Patients with Refractory Crohnʼs Disease Successfully Treated with Ustekinumab

Abstract

Using a novel subcutaneous dosing schedule, ustekinumab was successful in improving clinical, laboratory, and endoscopic markers of disease activity in patients with severe, refractory CD.